Zentalis Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Zentalis Pharmaceuticals Llc
ZNTL Stock  USD 3.50  0.27  8.36%   
Zentalis Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Zentalis Pharmaceuticals Llc investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Zentalis Pharmaceuticals financial statements helps investors assess Zentalis Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Zentalis Pharmaceuticals' valuation are summarized below:
Market Capitalization
249.4 M
Enterprise Value Revenue
7.7683
Revenue
40.6 M
Earnings Share
(2.50)
Revenue Per Share
0.572
There are over one hundred nineteen available fundamental gauges for Zentalis Pharmaceuticals, which can be analyzed over time and compared to other ratios. We recommend to confirm Zentalis Pharmaceuticals' prevalent fundamental drivers against the all of the trends between 2010 and 2024.
Check Zentalis Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Zentalis Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 469.1 K, Interest Income of 469.1 K or Depreciation And Amortization of 1.5 M, as well as many indicators such as Price To Sales Ratio of 23.9 K, Dividend Yield of 0.0 or PTB Ratio of 2.15. Zentalis financial statements analysis is a perfect complement when working with Zentalis Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Zentalis Pharmaceuticals Correlation against competitors.

Zentalis Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets376.7 M551.7 M184 M
Slightly volatile
Other Current Liabilities29.5 M54.2 M14.2 M
Slightly volatile
Total Current Liabilities40.3 M69.4 M20.6 M
Slightly volatile
Total Stockholder Equity306.3 M437.3 M145 M
Slightly volatile
Other Liabilities2.3 M3.1 M2.6 M
Pretty Stable
Property Plant And Equipment Net27.8 M41.7 M12.1 M
Slightly volatile
Accounts Payable9.9 M14.9 M6.1 M
Slightly volatile
Cash39.1 M28 M35.6 M
Slightly volatile
Non Current Assets Total54.9 M55 M31.3 M
Slightly volatile
Cash And Short Term Investments312.8 M482.9 M148 M
Slightly volatile
Net Receivables8.5 M8.1 M2.3 M
Slightly volatile
Good Will3 M3.4 M3.7 M
Slightly volatile
Common Stock Total Equity50.4 K53.1 K1.4 M
Slightly volatile
Common Stock Shares Outstanding46.9 M65.4 M29.8 M
Slightly volatile
Liabilities And Stockholders Equity376.7 M551.7 M184 M
Slightly volatile
Non Current Liabilities Total27.5 M44.9 M13.1 M
Slightly volatile
Other Current Assets11.8 M13.8 M5.4 M
Slightly volatile
Other Stockholder Equity687.1 M1.3 B295.7 M
Slightly volatile
Total Liabilities67.7 M114.3 M33.8 M
Slightly volatile
Property Plant And Equipment Gross47.1 M44.9 M10.8 M
Slightly volatile
Total Current Assets321.8 M496.7 M152.7 M
Slightly volatile
Capital Stock66.5 K70 K37.3 M
Slightly volatile
Non Current Liabilities Other1.7 M1.8 M880.8 K
Slightly volatile
Net Working Capital281.5 M427.4 M132.1 M
Slightly volatile
Intangible Assets7 M7.9 M8.6 M
Slightly volatile
Common Stock66.5 K70 K1.4 M
Slightly volatile
Property Plant Equipment5 M8.9 M2.6 M
Slightly volatile
Short and Long Term Debt Total30.1 M43.1 M11.6 M
Slightly volatile
Deferred Long Term Liabilities672.8 K756.9 K824.2 K
Slightly volatile
Short Term Debt1.7 M2.6 M1.1 M
Slightly volatile
Noncontrolling Interest In Consolidated Entity189 K198.9 K18.3 M
Slightly volatile
Short Term Investments388.6 M454.9 M309.1 M
Slightly volatile
Capital Surpluse830.3 M1.2 B624.9 M
Slightly volatile

Zentalis Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income469.1 K572.7 K415.3 K
Slightly volatile
Interest Income469.1 K572.7 K415.3 K
Slightly volatile
Depreciation And Amortization1.5 M1.4 M369.8 K
Slightly volatile
Selling General Administrative37.1 M59.4 M18.5 M
Slightly volatile
Other Operating Expenses162.7 M253.9 M82.7 M
Slightly volatile
Research Development124.7 M189.6 M63.7 M
Slightly volatile
Total Operating Expenses162.4 M252.6 M82.6 M
Slightly volatile
Reconciled Depreciation1.5 M1.4 M372.8 K
Slightly volatile
Cost Of Revenue798.6 K1.4 M361.8 K
Slightly volatile
Selling And Marketing Expenses1.1 M1.3 M1.4 M
Slightly volatile

Zentalis Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation29.6 M54.8 M12.9 M
Slightly volatile
Begin Period Cash Flow54.5 M45.7 M44.9 M
Slightly volatile
Depreciation1.5 M1.4 M369.8 K
Slightly volatile
Capital Expenditures553.9 K583 K863 K
Slightly volatile
Issuance Of Capital Stock212.9 M287 M96.7 M
Slightly volatile
Total Cash From Financing Activities206.9 M237.3 M94.1 M
Slightly volatile
End Period Cash Flow38.4 M30.7 M35.2 M
Slightly volatile
Change To Liabilities11.4 M17.9 M5.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio23.9 K26.9 K29.3 K
Slightly volatile
PTB Ratio2.152.266112.4114
Slightly volatile
Days Sales Outstanding19.1 K21.5 K23.4 K
Slightly volatile
Book Value Per Share4.766.6873.6501
Slightly volatile
Capex To Depreciation0.40.41974.12
Pretty Stable
PB Ratio2.152.266112.4114
Slightly volatile
EV To Sales22.5 K25.3 K27.6 K
Slightly volatile
Payables Turnover0.04980.09310.0396
Slightly volatile
Sales General And Administrative To Revenue279313341
Slightly volatile
Research And Ddevelopement To Revenue1.1 K1.2 K1.3 K
Slightly volatile
Capex To Revenue12.9714.5915.8897
Slightly volatile
Cash Per Share4.747.38313.4295
Slightly volatile
Days Payables Outstanding3.7 K3.9 K11.9 K
Slightly volatile
Income Quality0.90.71130.9414
Slightly volatile
Intangibles To Total Assets0.00640.00680.1958
Slightly volatile
Current Ratio6.027.16075.7017
Slightly volatile
Tangible Book Value Per Share4.556.62993.1615
Slightly volatile
Receivables Turnover0.01220.01370.015
Slightly volatile
Graham Number15.725.92212.0976
Slightly volatile
Shareholders Equity Per Share4.676.68543.3809
Slightly volatile
Debt To Equity0.120.09870.1191
Slightly volatile
Capex Per Share0.00850.00890.0233
Slightly volatile
Graham Net Net3.725.63562.6138
Slightly volatile
Revenue Per Share6.0E-47.0E-48.0E-4
Slightly volatile
Interest Debt Per Share0.960.65971.0014
Slightly volatile
Debt To Assets0.09530.07820.0954
Slightly volatile
Price Book Value Ratio2.152.266112.4114
Slightly volatile
Days Of Payables Outstanding3.7 K3.9 K11.9 K
Slightly volatile
Ebt Per Ebit0.781.11210.965
Slightly volatile
Company Equity Multiplier1.441.26161.5014
Slightly volatile
Long Term Debt To Capitalization0.110.08980.1066
Slightly volatile
Total Debt To Capitalization0.110.08980.1066
Slightly volatile
Debt Equity Ratio0.120.09870.1191
Slightly volatile
Quick Ratio6.057.16075.7187
Slightly volatile
Net Income Per E B T0.791.05530.9292
Slightly volatile
Cash Ratio0.380.40423.1216
Slightly volatile
Days Of Sales Outstanding19.1 K21.5 K23.4 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.811.00280.998
Slightly volatile
Price To Book Ratio2.152.266112.4114
Slightly volatile
Fixed Asset Turnover0.0430.04850.0528
Slightly volatile
Debt Ratio0.09530.07820.0954
Slightly volatile
Price Sales Ratio23.9 K26.9 K29.3 K
Slightly volatile
Asset Turnover3.0E-43.0E-43.0E-4
Slightly volatile
Price Fair Value2.152.266112.4114
Slightly volatile

Zentalis Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.2 B1.9 B1.2 B
Slightly volatile
Enterprise Value1.1 B1.9 B1.1 B
Slightly volatile

Zentalis Fundamental Market Drivers

Cash And Short Term Investments482.9 M

Zentalis Upcoming Events

6th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Zentalis Pharmaceuticals Financial Statements

Zentalis Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Zentalis Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue281 K295.1 K
Cost Of Revenue1.4 M798.6 K
Sales General And Administrative To Revenue 313.46  278.63 
Research And Ddevelopement To Revenue1.2 K1.1 K
Capex To Revenue 14.59  12.97 
Ebit Per Revenue-1.5 K-1.6 K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Zentalis Pharmaceuticals is a strong investment it is important to analyze Zentalis Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zentalis Pharmaceuticals' future performance. For an informed investment choice regarding Zentalis Stock, refer to the following important reports:
How To Invest In Zentalis
Details
Is Zentalis Stock a good investment?
Details
What is Zentalis Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Zentalis Pharmaceuticals Correlation against competitors.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.50)
Revenue Per Share
0.572
Return On Assets
(0.25)
Return On Equity
(0.43)
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY